This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2012 Mar 10;30(8):765-6.

doi: 10.1200/JCO.2011.39.6390. Epub 2012 Jan 23.

Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors

Dejan Juric, José Baselga

PMID: 22271482
DOI: 10.1200/JCO.2011.39.6390

Editorial

Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors

Dejan Juric et al. J Clin Oncol. 2012.

. 2012 Mar 10;30(8):765-6.

doi: 10.1200/JCO.2011.39.6390. Epub 2012 Jan 23.

Authors

Dejan Juric, José Baselga

PMID: 22271482
DOI: 10.1200/JCO.2011.39.6390

No abstract available

PubMed Disclaimer

Comment on

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. Janku F, et al. J Clin Oncol. 2012 Mar 10;30(8):777-82. doi: 10.1200/JCO.2011.36.1196. Epub 2012 Jan 23. J Clin Oncol. 2012. PMID: 22271473 Free PMC article.

Similar articles

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. Janku F, et al. J Clin Oncol. 2012 Mar 10;30(8):777-82. doi: 10.1200/JCO.2011.36.1196. Epub 2012 Jan 23. J Clin Oncol. 2012. PMID: 22271473 Free PMC article.
Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies.
Eskander RN, Tewari KS. Eskander RN, et al. Expert Rev Clin Pharmacol. 2014 Nov;7(6):847-58. doi: 10.1586/17512433.2014.968554. Epub 2014 Oct 10. Expert Rev Clin Pharmacol. 2014. PMID: 25301678 Review.
The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress.
Bahrami A, Khazaei M, Shahidsales S, Hassanian SM, Hasanzadeh M, Maftouh M, Ferns GA, Avan A. Bahrami A, et al. J Cell Biochem. 2018 Jan;119(1):213-222. doi: 10.1002/jcb.26136. Epub 2017 Jul 4. J Cell Biochem. 2018. PMID: 28513879 Review.
Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions.
Bartlett JM. Bartlett JM. Clin Breast Cancer. 2010 Nov;10 Suppl 3:S86-95. doi: 10.3816/CBC.2010.s.017. Clin Breast Cancer. 2010. PMID: 21115427 Review.
PI3K pathway inhibitors approach junction.
Holmes D. Holmes D. Nat Rev Drug Discov. 2011 Aug 1;10(8):563-4. doi: 10.1038/nrd3527. Nat Rev Drug Discov. 2011. PMID: 21804582 No abstract available.

See all similar articles

Cited by

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.
Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Tsimberidou AM, et al. Clin Cancer Res. 2012 Nov 15;18(22):6373-83. doi: 10.1158/1078-0432.CCR-12-1627. Epub 2012 Sep 10. Clin Cancer Res. 2012. PMID: 22966018 Free PMC article.
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.
Gonzalez-Angulo AM, Blumenschein GR Jr. Gonzalez-Angulo AM, et al. Cancer Treat Rev. 2013 Jun;39(4):313-20. doi: 10.1016/j.ctrv.2012.11.002. Epub 2012 Dec 6. Cancer Treat Rev. 2013. PMID: 23218708 Free PMC article.
Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.
Ando Y, Inada-Inoue M, Mitsuma A, Yoshino T, Ohtsu A, Suenaga N, Sato M, Kakizume T, Robson M, Quadt C, Doi T. Ando Y, et al. Cancer Sci. 2014 Mar;105(3):347-53. doi: 10.1111/cas.12350. Epub 2014 Feb 13. Cancer Sci. 2014. PMID: 24405565 Free PMC article. Clinical Trial.
Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.
Nichols AC, Black M, Yoo J, Pinto N, Fernandes A, Haibe-Kains B, Boutros PC, Barrett JW. Nichols AC, et al. BMC Pharmacol Toxicol. 2014 Nov 27;15:66. doi: 10.1186/2050-6511-15-66. BMC Pharmacol Toxicol. 2014. PMID: 25428177 Free PMC article.
Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer.
Khatpe AS, Adebayo AK, Herodotou CA, Kumar B, Nakshatri H. Khatpe AS, et al. Cancers (Basel). 2021 Jan 20;13(3):369. doi: 10.3390/cancers13030369. Cancers (Basel). 2021. PMID: 33498407 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal